ARCTHealthcare · BiotechnologyThe 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. hold a median 12-month price target of $20 — +55.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Arcturus Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (80): Analysts have, on balance, been raising their forecasts.
Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ARCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +55.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | BTIG | Maintains | Buy | $23 → $20 |
| 24 Sept 2026 | Citigroup | Upgrade | Buy | $8.00 → $20 |
| 2 July 2026 | Freedom Broker | Initiates | Buy | $27 |
| 2 July 2026 | Freedom Broker | Initiates | Buy | — |
| 18 Mar 2026 | B. Riley Securities | Initiates | Buy | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 4 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 4 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 6 Jan 2026 | Citigroup | Maintains | Neutral | — |
| 13 Nov 2025 | Citigroup | Maintains | Neutral | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 24 Oct 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 23 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 23 Oct 2025 | Guggenheim | Downgrade | Neutral | — |
| 23 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 22 Oct 2025 | BTIG | Maintains | Buy | — |
| 22 Oct 2025 | Guggenheim | Downgrade | Neutral | — |
| 4 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $60 |
| 22 Aug 2025 | Leerink Partners | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Arcturus Therapeutics Holdings, Inc. returned −39.3% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 12% of US stocks
Cheaper than 42% of US stocks
Cheaper than 72% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arcturus Therapeutics Holdings, Inc. has a market value of $369.5M and an enterprise value of $200.9M.
Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter shrank 89.5% year on year.
Net income over the same four quarters: −$93.3M, a −498.2% net margin.
Diluted earnings per share, trailing twelve months: $−3.31.
Free cash flow in the twelve months to 30 June 2026: −$72.8M.
Trailing P/E: 10.1×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Arcturus Therapeutics Holdings, Inc. employs 106 people — $177K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| ARCTArcturus Therapeutics Holdings, Inc. | $369.5M | 69 |
| GALTGalectin Therapeutics, Inc. | $367.1M | 73 |
| INDPIndaptus Therapeutics, Inc. | $364.0M | 25 |
| IRDOpus Genetics, Inc. | $363.0M | 60 |
| SCTXScribe Therapeutics, Inc. | $362.8M | 2 |
| KYTXKyverna Therapeutics, Inc. | $373.5M | 41 |
| ENTAEnanta Pharmaceuticals, Inc. | $352.4M | 90 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcturus Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases, according to Zacks Investment Research.
Why it matters — The article highlights Arcturus among leading RNA therapeutics companies, underscoring its position in the sector's innovation wave.
Arcturus Therapeutics presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, and outlined plans to introduce a next-generation delivery platform into the program.
Why it matters — ARCT watchers would care because the Phase II data update and the planned next-generation delivery platform could influence the development trajectory of a key pipeline candidate.
Arcturus Therapeutics discussed Phase II data for ornithine transcarbamylase (OTC) deficiency and outlined advances in its mRNA liver therapeutics platform, according to a Seeking Alpha transcript of the company's presentation.
Why it matters — ARCT watchers would care because the update touches on the company's lead liver-targeted mRNA program and its broader platform direction.
Arcturus Therapeutics announced encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced its LUNAR 2.0 next-generation mRNA delivery platform along with additional liver pipeline programs.
Why it matters — The interim Phase 2 data and the introduction of LUNAR 2.0 signal progress in Arcturus's liver therapeutic pipeline and its next-generation delivery technology.
Seeking Alpha covers Arcturus Therapeutics' mRNA pipeline, highlighting ARCT-810 for OTC deficiency as a near-term catalyst with promising phase 2 interim data that normalized glutamine and ammonia levels. The drug has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, with an upcoming Sep. 23 presentation on ARCT-810 noted as potentially significant.
Why it matters — ARCT watchers would care because the upcoming Sep. 23 presentation on ARCT-810 represents a near-term catalyst for the company's lead OTC deficiency program, though small trial sizes mean the results should be treated as hypothesis-generating.
The 13 Wall Street analysts covering Arcturus Therapeutics Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $9 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Arcturus Therapeutics Holdings, Inc., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcturus Therapeutics Holdings, Inc. 69 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Arcturus Therapeutics Holdings, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +55.4% from the last close, and Ticker Nerd's factor model ranks Arcturus Therapeutics Holdings, Inc. 69 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arcturus Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $41 over the next 12 months.
Arcturus Therapeutics Holdings, Inc. returned -39.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders.
The most recent item we track (Zacks Investment Research, 28 Sept 2026): "4 RNA Therapeutics Stocks Leading the Next Wave of Innovation". RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases, according to Zacks Investment Research.
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics and vaccines for infectious diseases and rare disorders. The company’s core platforms include STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system designed to help deliver RNA medicines into the body. Its current work centers on liver and respiratory rare diseases, with programs aimed at conditions such as cystic fibrosis and ornithine transcarbamylase deficiency, alongside vaccine candidates for seasonal and pandemic influenza and COVID-19. Arcturus Therapeutics also supports drug substance and drug product manufacturing capabilities as part of its RNA medicine development and commercialization activities. Headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a specialized role in the biotechnology market by advancing RNA-based approaches for both therapeutic and preventive applications.
CEO Mr. Joseph E. Payne M.Sc. · 106 employees · United States · https://arcturusrx.com
